Published in Life Sci on November 13, 2009
Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J (2013) 1.07
Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine. Curr Pharmacogenomics Person Med (2011) 0.83
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists. Br J Pharmacol (2013) 0.81
Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination. AAPS J (2013) 0.75
The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. Pharmacol Res Perspect (2015) 0.75
Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. Eur J Clin Pharmacol (2016) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos (2010) 3.06
T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett (2003) 2.52
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ J (2010) 1.49
Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening. Ann Nucl Med (2013) 1.41
Giant cell arteritis with polymyalgia rheumatica associated with influenza vaccination. J Dermatol (2011) 1.39
OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos (2006) 1.19
Structural analysis of obscurin gene in hypertrophic cardiomyopathy. Biochem Biophys Res Commun (2007) 1.19
Structure-based targeting of bioactive proteins into cypovirus polyhedra and application to immobilized cytokines for mammalian cell culture. Biomaterials (2009) 1.13
Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res (2006) 1.07
Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos (2014) 1.06
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos (2009) 1.05
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother (2009) 1.04
Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr (2007) 1.03
Metabolic syndrome among pre- and post-menopausal rural women in Bangladesh: result from a population-based study. BMC Res Notes (2013) 0.96
Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur J Pharmacol (2006) 0.96
Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos (2008) 0.93
Social isolation stress induces ATF-7 phosphorylation and impairs silencing of the 5-HT 5B receptor gene. EMBO J (2009) 0.92
Prevalence of metabolic syndrome among rural Bangladeshi women. Diabetes Res Clin Pract (2011) 0.91
Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol Endocrinol (2003) 0.91
A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos (2009) 0.91
Association of age at menarche with metabolic syndrome and its components in rural Bangladeshi women. Nutr Metab (Lond) (2012) 0.90
Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. Chem Res Toxicol (2007) 0.89
Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos (2010) 0.88
Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab Dispos (2011) 0.88
Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family. Toxicol Sci (2010) 0.88
Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorg Med Chem Lett (2013) 0.87
Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem (2010) 0.87
Distribution of rat organic anion transporting polypeptide-E (oatp-E) in the rat eye. Invest Ophthalmol Vis Sci (2003) 0.86
11C-methionine PET of acute myocardial infarction. J Nucl Med (2009) 0.86
Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. Drug Metab Dispos (2008) 0.86
Value of FDG-PET/CT using unfractionated heparin for managing primary cardiac lymphoma and several key findings. J Nucl Cardiol (2011) 0.86
Stunned myocardium in transient left ventricular apical ballooning: a serial study of dual I-123 BMIPP and Tl-201 SPECT. J Nucl Cardiol (2008) 0.86
Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet (2011) 0.85
Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res (2014) 0.84
Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging. Am J Nucl Med Mol Imaging (2013) 0.84
Simultaneous quantification of prostaglandins, isoprostane and thromboxane in cell-cultured medium using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.83
Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch Toxicol (2009) 0.83
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos (2011) 0.83
Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity. Clin Nucl Med (2013) 0.82
Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. Drug Metab Dispos (2009) 0.81
Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab Pharmacokinet (2010) 0.80
Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity. Biochemistry (2004) 0.80
Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos (2007) 0.80
Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung (2004) 0.80
Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther (2008) 0.80
Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol (2006) 0.80
Metabolism of ticlopidine in rats: identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide. Drug Metab Dispos (2009) 0.80
Reproducibility and validity of the Japanese version of the Western Ontario Rotator Cuff Index. J Orthop Sci (2013) 0.80
Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides. Oligonucleotides (2006) 0.79
In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides. Nucleic Acids Symp Ser (Oxf) (2007) 0.79
Amyloid imaging mismatch. Clin Nucl Med (2012) 0.79
Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrate. Drug Metab Pharmacokinet (2007) 0.79
Disruption of components of vascular endothelial growth factor angiogenic signalling system in metabolic syndrome. Findings from a study conducted in rural Bangladeshi women. Thromb Haemost (2013) 0.79
Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispos (2010) 0.78
Glutathione S-transferase pi trapping method for generation and characterization of drug-protein adducts in human liver microsomes using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal (2012) 0.78
Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model. Arch Toxicol (2010) 0.78
Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid. Xenobiotica (2011) 0.78
A cross-sectional survey of blood pressure of a coastal city's resident victims of the 2011 Tohoku tsunami. Am J Hypertens (2013) 0.77
Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. Pharm Res (2012) 0.77
Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Drug Metab Pharmacokinet (2010) 0.77
Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm Res (2005) 0.77
6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Drug Metab Dispos (2014) 0.77
Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice. J Pharmacol Sci (2013) 0.77
Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet (2011) 0.77
Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos (2010) 0.77
Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue. Drug Metab Dispos (2014) 0.76
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug Metab Dispos (2011) 0.76
PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver. J Pharm Pharmacol (2010) 0.76
Transporter mRNA expression in a conditionally immortalized rat small intestine epithelial cell line (TR-SIE). Drug Metab Pharmacokinet (2004) 0.76
Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. Drug Metab Pharmacokinet (2003) 0.76
Development of a pretreatment method for amyloid beta-protein analysis based on the effect of acetic acid on the dissolution of plasma polypeptides. Biomed Chromatogr (2008) 0.76
Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorg Med Chem (2013) 0.76
Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor. Drug Metab Dispos (2013) 0.76
Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors. J Pharm Sci (2011) 0.75
Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab Pharmacokinet (2009) 0.75
Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats. Pharm Res (2012) 0.75
Computer simulation of clinical electrophysiological study. Pacing Clin Electrophysiol (2012) 0.75
Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. Eur J Pharm Sci (2012) 0.75
Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys. Arzneimittelforschung (2004) 0.75
Design and synthesis of oatp subtype-specific antisense oligonucleotides having 2'-O,4'-C-ethylene-bridged nucleic acids (ENA). Nucleic Acids Res Suppl (2003) 0.75
Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis. Intern Med (2014) 0.75
In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos (2011) 0.75
Pharmacokinetics and disposition of DY-9760e, a novel calmodulin antagonist, in rats and monkeys. Arzneimittelforschung (2005) 0.75
Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys. Drug Metab Dispos (2010) 0.75
Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica (2014) 0.75